Eylea Shows Greater Visual Acuity Gain in DME Trial

Regeneron announced results from an effectiveness study sponsored by the National Institutes of Health (NIH) in patients with diabetic macular edema (DME) treated with Eylea (aflibercept) Injection compared to Avastin (bevacizumab; Genentech) and Lucentis (ranibizumab; Genentech).

The study was designed to determine if one of three different anti-VEGF therapies is superior to the others for the treatment of diabetic macular edema. In the study, 660 patients were randomized to receive either Eylea 2mg, bevacizumab 1.25mg, or ranibizumab 0.3mg. Patients were treated with focal/grid laser at or after the 24 week visit if the OCT central subfield thickness was ≥250 microns or there was edema that was threatening the fovea, and if the eye did not improve on OCT or visual acuity from the last two consecutive injections.

Eylea demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to Avastin and Lucentis. Fewer patients in the Eylea treatment group received criteria-based macular laser treatments than those treated with the other two treatment groups.

Eylea is a vascular endothelial growth factor (VEGF) inhibitor, approved for the treatment of wet age-related macular degeneration (AMD), macular edema following RVO, and diabetic macular edema (DME).

Want to read more?